Fig 1.
Radar diagram of SeDeM expert ODT.
Fig 2.
SeDeM diagram (Radar Plot) of ludipress, flurbiprofen and formulations (F1-F9).
(A) Flurbiprofen (API) (B) Ludipress (Superdisintegrant) (C) Formulation F1 (D) Formulation F2 (E) Formulation F3 (F) Formulation F4 (G) Formulation F5 (H) Formulation F6 (I) Formulation F7 (J) Formulation F8 (K) Formulation F9.
Table 1.
Experimental values of parameters / indices, mean incidence factors, and indices of flurbiprofen and ludipress.
Table 2.
Composition of flurbiprofen-ODT formulations (F1-F9).
Table 3.
Experimental values of parameters / indices, mean incidence factors and indices of (F1 –F9).
Fig 3.
Thermal stability and surface morphology of sample and API respectively.
(A) Thermal gravimetric analysis (TGA) and Differential scanning calorimetry (DSC) of Optimized Flurbiprofen–ODT Formulation. (B) SEM analysis of flurbiprofen (API).
Fig 4.
Response surface plots of flurbiprofen–ODT tablets (F1 –F9) indicating the effect of independent variables.
(A) Disintegration Time (B) Hardness and, (C) Friability.
Fig 5.
Response surface plots of optimized flurbiprofen–ODT tablets (F4) indicating the effect of independent variables.
(A) Disintegration time (B) Hardness and, (C) Friability.
Table 4.
Physicochemical quality attributes of flurbiprofen–ODT formulations (F1- F9).
Fig 6.
Graphical representation of in vitro release pattern and release kinetics model of formulations F1- F9 at 7.2.
(A) Invitro Drug release pattern for formulations (F1- F9). (B) First Order, Higuchi, Hixon Crowell, and Weibull Model of formulations (F1- F9).
Table 5.
Release kinetics of formulations (F1-F9) at pH 7.2.
Fig 7.
Shelf-life estimation of F1 –F9 at accelerated state.
Table 6.
Stability studies of flurbiprofen–ODT formulations at accelerated conditions.